Amgen Inc. on Thursday named Jonathan M. Peacock as its chief financial officer, effective Sept. 1.

The Thousand Oaks biotech said Peacock, 52, has been CFO and administration officer at Novartis Pharmaceutical AG, a Swiss drugmaker, since 2005. Prior to that, he was a partner at consulting firm McKinsey & Co. and, earlier, a partner at Price Waterhouse in New York and London.

Peacock succeeds Michael A. Kelly, who has been acting CFO since Robert Bradway was promoted to the new position of chief operating officer in April.

“I am delighted to have a leader of Jonathan’s talent, vision and international experience join Amgen at a time when we are expanding globally,” said Chief Executive Kevin Sharer in a statement.

Shares were down 7 cents, or less than a percent, to $52.55 in midday trading on the Nasdaq.